Intestinal dysbiosis and lowered serum lipopolysaccharide-binding protein in Parkinson's disease
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The intestine is one of the first affected organs in Parkinson's disease (PD). PD subjects show abnormal staining for Escherichia coli and α-synuclein in the colon. METHODS: We recruited 52 PD patients and 36 healthy cohabitants. We measured serum markers and quantified the numbers of 19 fecal bacterial groups/genera/species by quantitative RT-PCR of 16S or 23S rRNA. Although the six most predominant bacterial groups/genera/species covered on average 71.3% of total intestinal bacteria, our analysis was not comprehensive compared to metagenome analysis or 16S rRNA amplicon sequencing. RESULTS: In PD, the number of Lactobacillus was higher, while the sum of analyzed bacteria, Clostridium coccoides group, and Bacteroides fragilis group were lower than controls. Additionally, the sum of putative hydrogen-producing bacteria was lower in PD. A linear regression model to predict disease durations demonstrated that C. coccoides group and Lactobacillus gasseri subgroup had the largest negative and positive coefficients, respectively. As a linear regression model to predict stool frequencies showed that these bacteria were not associated with constipation, changes in these bacteria were unlikely to represent worsening of constipation in the course of progression of PD. In PD, the serum lipopolysaccharide (LPS)-binding protein levels were lower than controls, while the levels of serum diamine oxidase, a marker for intestinal mucosal integrity, remained unchanged in PD. CONCLUSIONS: The permeability to LPS is likely to be increased without compromising the integrity of intestinal mucosa in PD. The increased intestinal permeability in PD may make the patients susceptible to intestinal dysbiosis. Conversely, intestinal dysbiosis may lead to the increased intestinal permeability. One or both of the two mechanisms may be operational in development and progression of PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Increased gut permeability with intestine α-synuclein accumulation, elevated blood and brain levels of TLR2 and TLR4, and reduced blood levels of the LPS-binding protein have been detected in subjects with”
From The Role of Microbiota-Gut-Brain Axis in Neuropsychiatric and Neurological Disorders (2021) · cites this paper as [413]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As with most of the diseases, PD patients have a different microbiota composition compared to healthy controls or patients affected by other neurological disorders (174–176).”
From The gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology (2020) · cites this paper as [174]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A clinical study revealed that the level of serum LPS-binding protein in patients with Parkinson's disease was lower than that in controls, indicating that increased intestinal permeability and increased invasion of Gram-negative bacteria leads to an increase in LPS in the circulatory system.148”
From The role of gut dysbiosis in Parkinson’s disease: mechanistic insights and therapeutic options (2021) · cites this paper as [148]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“serum from PD patients contains low levels of LPS binding protein [145,146], which are indicative of a chronic systemic exposure to LPS and gram negative endobacteria [147,148,149]”
From The Interplay between Gut Microbiota and Parkinson’s Disease: Implications on Diagnosis and Treatment (2022) · cites this paper as [145]
In the citing paper
“Reduced number of Prevotella may be associated with decreased mucin synthesis causing increased gut permeability [413].”
From The Role of Microbiota-Gut-Brain Axis in Neuropsychiatric and Neurological Disorders (2021) · cites this paper as [413]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777 · cited 1×
“Postmortem studies of non-PD subjects disclosed incidental α-synuclein-positive Lewy bodies in the gastrointestinal tract, the olfactory system, and the cardiac sympathetic system, which suggests that α-synuclein pathology in PD may start in these tissues [2].”
BackgroundDiet rapidly and reproducibly alters the human gut microbiome
David, L. A., Maurice, C. F., Carmody, R. N., Gootenberg, D. B., Button, J. E., Wolfe, B. E., Ling, A. V., Devlin, A. S., Varma, Y., Fischbach, M. A., et al. (2014) · Nature · doi:10.1038/nature12820 · Cited by 10,100
(2023) · doi:10.1126/science · Cited by 6,063
Gut Microbiota from Twins Discordant for Obesity Modulate Metabolism in Mice
Ridaura, V. K., Faith, J. J., Rey, F. E., Cheng, J., Duncan, A. E., Kau, A. L., Griffin, N. W., Lombard, V., Henrissat, B., Bain, J. R., et al. (2013) · Science · doi:10.1126/science.1241214 · Cited by 3,788 · cited 2×
“Direct evidence supporting the notion that intestinal microbiota determines a clinical phenotype has been recently reported in obesity [9].”
Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030
Dorsey, E. R., Constantinescu, R., Thompson, J. P., Biglan, K. M., Holloway, R. G., Kieburtz, K., Marshall, F. J., Ravina, B. M., Schifitto, G., Siderowf, A., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000247740.47667.03 · Cited by 2,472 · cited 1×
“PD is predicted to affect more than 10 million people worldwide by the year 2030 [1].”
BackgroundGut microbiota are related to Parkinson's disease and clinical phenotype
Scheperjans, F., Aho, V., Pereira, P. A. B., Koskinen, K., Paulin, L., Pekkonen, E., Haapaniemi, E., Kaakkola, S., Eerola‐Rautio, J., Pohja, M., et al. (2015) · Movement Disorders · doi:10.1002/mds.26069 · Cited by 1,968 · cited 3×
“In contrast to Prevotella, the count of Lactobacillus was increased 22-fold in the previous report [10], and 6.”
BackgroundResultOccurrence, Classification, and Biological Function of Hydrogenases: An Overview
Vignais, P. M., & Billoud, B. (2007) · Chemical Reviews · doi:10.1021/cr050196r · Cited by 1,578 · cited 1×
“According to an extensive review of bacterial hydrogenases [25], B.”
BackgroundDisease duration and the integrity of the nigrostriatal system in Parkinson’s disease
Kordower, J. H., Olanow, C. W., Dodiya, H. B., Chu, Y., Beach, T. G., Adler, C. H., Halliday, G. M., & Bartus, R. T. (2013) · Brain · doi:10.1093/brain/awt192 · Cited by 1,286
Colonic bacterial composition in Parkinson's disease
Keshavarzian, A., Green, S. J., Engen, P. A., Voigt, R. M., Naqib, A., Forsyth, C. B., Mutlu, E., & Shannon, K. M. (2015) · Movement Disorders · doi:10.1002/mds.26307 · Cited by 1,281 · cited 1×
“Intestinal microbiota in PD was recently published [10, 11].”
BackgroundForsyth, C. B., Shannon, K. M., Kordower, J. H., Voigt, R. M., Shaikh, M., Jaglin, J. A., Estes, J. D., Dodiya, H. B., & Keshavarzian, A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028032 · Cited by 974 · cited 4×
“In PD, intestinal permeability is increased and the hyperpermeability is correlated with increased intestinal staining for Escherichia coli; nitrotyrosine, a marker for protein oxidation; and α-synuclein [7].”
BackgroundResultInfluentialFrequency of Bowel Movements and the Future Risk of Parkinson’s Disease
Abbott, R. D., Petrovitch, H., White, L. R., Masaki, K. H., Tanner, C. M., Curb, J. D., Grandinetti, A., Blanchette, P. L., Popper, J. S., & Ross, G. W. (2001) · Neurology · doi:10.1212/wnl.57.3.456 · Cited by 839
Braak, H., Del Tredici, K., Bratzke, H., Hamm-Clement, J., Sandmann-Keil, D., & Rüb, U. (2002) · Journal of Neurology · doi:10.1007/s00415-002-1301-4 · Cited by 708 · cited 1×
“Appearance of intestinal α-synuclein in aged non-PD subjects [27], as well as presymptomatic appearance of intestinal α-synuclein in PD patients [28], imply that the PD pathology may start from the intestine.”
BackgroundMalinen, E., Rinttila, T., Kajander, K., Matto, J., Kassinen, A., Krogius, L., Saarela, M., Korpela, R., & Palva, A. (2005) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2005.40312.x · Cited by 699 · cited 3×
“As the increased Lactobacillus was also observed in diabetes mellitus type 2 [21] and the constipation-type irritable bowel syndrome [42], it may not have disease specificity.”
BackgroundRome III: New standard for functional gastrointestinal disorders.
Drossman, D. A., & Dumitrascu, D. L. (2006) · PubMed · Cited by 660
Fujiwara, Y., Suzuki, H., Yasunaga, M., Sugiyama, M., Ijuin, M., Sakuma, N., Inagaki, H., Iwasa, H., Ura, C., Yatomi, N., et al. (2010) · Geriatrics & Gerontology International · doi:10.1111/j.1447-0594.2010.00585.x · Cited by 631 · cited 1×
“The severities of PD were evaluated using the Hoehn and Yahr scale, the Unified Parkinson’s Disease Rating Scale (UPDRS) parts I-IV, the Mini Mental Sate Examination (MMSE), the Japanese version of the Montreal Cognitive Assessment (MoCA-J) [12], the Frontal Assessment Battery at bedside (FAB), and the Odor Stick Iden…”
MethodColonic inflammation in Parkinson's disease
Devos, D., Lebouvier, T., Lardeux, B., Biraud, M., Rouaud, T., Pouclet, H., Coron, E., Bruley des Varannes, S., Naveilhan, P., Nguyen, J.-M., et al. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.09.007 · Cited by 627
A timeline for Parkinson's disease
Hawkes, C. H., Del Tredici, K., & Braak, H. (2010) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2009.08.007 · Cited by 594 · cited 1×
“Similarly, in PD, accumulation of α-synuclein in the enteric nervous system could commence 20 years before the onset of degenerative changes in the central nervous system and the associated motor symptoms in PD [3].”
BackgroundIsolation of a lipopolysaccharide-binding acute phase reactant from rabbit serum.
Tobias, P. S., Soldau, K., & Ulevitch, R. J. (1986) · The Journal of experimental medicine · doi:10.1084/jem.164.3.777 · Cited by 541
Alpha-synuclein in colonic submucosa in early untreated Parkinson’s disease
Shannon, K. M., Keshavarzian, A., Mutlu, E., Dodiya, H. B., Daian, D., Jaglin, J. A., & Kordower, J. H. (2012) · Movement Disorders · doi:10.1002/mds.23838 · Cited by 469 · cited 1×
“Appearance of intestinal α-synuclein in aged non-PD subjects [27], as well as presymptomatic appearance of intestinal α-synuclein in PD patients [28], imply that the PD pathology may start from the intestine.”
BackgroundSato, J., Kanazawa, A., Ikeda, F., Yoshihara, T., Goto, H., Abe, H., Komiya, K., Kawaguchi, M., Shimizu, T., Ogihara, T., et al. (2014) · Diabetes Care · doi:10.2337/dc13-2817 · Cited by 437 · cited 2×
“As the increased Lactobacillus was also observed in diabetes mellitus type 2 [21] and the constipation-type irritable bowel syndrome [42], it may not have disease specificity.”
BackgroundSelf-citationThe role of small intestinal bacterial overgrowth in Parkinson's disease
Fasano, A., Bove, F., Gabrielli, M., Petracca, M., Zocco, M. A., Ragazzoni, E., Barbaro, F., Piano, C., Fortuna, S., Tortora, A., et al. (2013) · Movement Disorders · doi:10.1002/mds.25522 · Cited by 344
Kelly, L. P., Carvey, P. M., Keshavarzian, A., Shannon, K. M., Shaikh, M., Bakay, R. A. E., & Kordower, J. H. (2014) · Movement Disorders · doi:10.1002/mds.25736 · Cited by 308 · cited 1×
“Additional supporting evidence is that oral administration of LPS is able to induce intestinal PD pathology in rodents [31, 32].”
BackgroundSensitive Quantitative Detection of Commensal Bacteria by rRNA-Targeted Reverse Transcription-PCR
Matsuda, K., Tsuji, H., Asahara, T., Kado, Y., & Nomoto, K. (2007) · Applied and Environmental Microbiology · doi:10.1128/aem.01224-06 · Cited by 294 · cited 1×
“To quantify the bacteria present in the sample, we extracted total RNA fractions from feces by the previously described method [17, 18], and examined the composition of gut microbiota with the Yakult intestinal Flora-SCAN (YIF-SCAN(1)), which exploited RT-quantitative PCR (qPCR) of bacterial 16S or 23S rRNA [19–21].”
MethodSelf-citationSmall intestinal bacterial overgrowth in Parkinson's disease
Tan, A. H., Mahadeva, S., Thalha, A. M., Gibson, P. R., Kiew, C. K., Yeat, C. M., Ng, S. W., Ang, S. P., Chow, S. K., Tan, C. T., et al. (2014) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2014.02.019 · Cited by 274
Florent, C., Flourie, B., Leblond, A., Rautureau, M., Bernier, J. J., & Rambaud, J. C. (1985) · Journal of Clinical Investigation · doi:10.1172/jci111738 · Cited by 264 · cited 1×
“Lactulose is a synthetic disaccharide that can be catalyzed only by intestinal bacteria in human, and a large amount of hydrogen is produced by bacterial catalysis of lactulose [45].”
BackgroundMatsuda, K., Tsuji, H., Asahara, T., Matsumoto, K., Takada, T., & Nomoto, K. (2009) · Applied and Environmental Microbiology · doi:10.1128/aem.01843-08 · Cited by 258 · cited 10×
“The comparison of the counts of the six bacteria and total bacterial count showed that 71.3 ± 9.4% (mean and SD) of total intestinal bacteria were covered by the six predominant bacterial groups/genera/species in YIF-SCAN [18].”
BackgroundMethodSelf-citationOxidative damage in Parkinson disease: Measurement using accurate biomarkers
Seet, R. C. S., Lee, C.-Y. J., Lim, E. C. H., Tan, J. J. H., Quek, A. M. L., Chong, W.-L., Looi, W.-F., Huang, S.-H., Wang, H., Chan, Y.-H., et al. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2009.11.026 · Cited by 257 · cited 1×
“Others, however, report that IL-6 is not elevated in PD patients [52].”
BackgroundLuk, G. D., Bayless, T. M., & Baylin, S. B. (1980) · Journal of Clinical Investigation · doi:10.1172/jci109836 · Cited by 249 · cited 2×
“We also observed that the serum level of DAO, a marker for intestinal mucosal integrity [16], was not decreased in PD.”
BackgroundThe lipopolysaccharide Parkinson’s disease animal model: mechanistic studies and drug discovery
Dutta, G., Zhang, P., & Liu, B. (2008) · Fundamental & Clinical Pharmacology · doi:10.1111/j.1472-8206.2008.00616.x · Cited by 235 · cited 1×
“Additional supporting evidence is that oral administration of LPS is able to induce intestinal PD pathology in rodents [31, 32].”
BackgroundGutsmann, T., Müller, M., Carroll, S. F., MacKenzie, R. C., Wiese, A., & Seydel, U. (2001) · Infection and Immunity · doi:10.1128/iai.69.11.6942-6950.2001 · Cited by 229 · cited 2×
“LBP binds to LPS, which is contained in the cell wall of Gram-negative bacteria, is increased in response to acute LPS invasion and decreased in chronic LPS invasion [15].”
BackgroundInflammation is genetically implicated in Parkinson’s disease
Dzamko, N., Geczy, C. L., & Halliday, G. M. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2014.10.028 · Cited by 222
Fu, Y., Ito, M., Fujita, Y., Ito, M., Ichihara, M., Masuda, A., Suzuki, Y., Maesawa, S., Kajita, Y., Hirayama, M., et al. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.02.016 · Cited by 213 · cited 2×
“We analyzed the counts of hydrogen-producing bacteria because per os administration of hydrogen water is protective against PD in rats [22] and mice [23].”
BackgroundSelf-citationMartin, T. R., Mathison, J. C., Tobias, P. S., Letúrcq, D. J., Moriarty, A. M., Maunder, R. J., & Ulevitch, R. J. (1992) · Journal of Clinical Investigation · doi:10.1172/jci116106 · Cited by 213 · cited 1×
“LBP opsonizes LPS, which is the cell wall constituent of Gram-negative bacteria [49].”
BackgroundFujita, K., Seike, T., Yutsudo, N., Ohno, M., Yamada, H., Yamaguchi, H., Sakumi, K., Yamakawa, Y., Kido, M. A., Takaki, A., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007247 · Cited by 201 · cited 2×
“We analyzed the counts of hydrogen-producing bacteria because per os administration of hydrogen water is protective against PD in rats [22] and mice [23].”
BackgroundHelicobacter pylori eradication and l-dopa absorption in patients with PD and motor fluctuations
Pierantozzi, M., Pietroiusti, A., Brusa, L., Galati, S., Stefani, A., Lunardi, G., Fedele, E., Sancesario, G., Bernardi, G., Bergamaschi, A., et al. (2006) · Neurology · doi:10.1212/01.wnl.0000221672.01272.ba · Cited by 199
Ohigashi, S., Sudo, K., Kobayashi, D., Takahashi, O., Takahashi, T., Asahara, T., Nomoto, K., & Onodera, H. (2013) · Digestive Diseases and Sciences · doi:10.1007/s10620-012-2526-4 · Cited by 180 · cited 1×
“In three previous studies, the numbers of obligate anaerobe were decreased in patients with irritable bowel syndrome [42], colorectal cancer [20], and type 2 diabetes [21].”
BackgroundSelf-citationPrevalence of small intestinal bacterial overgrowth in Parkinson’s disease
Gabrielli, M., Bonazzi, P., Scarpellini, E., Bendia, E., Lauritano, E. C., Fasano, A., Ceravolo, M. G., Capecci, M., Rita Bentivoglio, A., Provinciali, L., et al. (2011) · Movement Disorders · doi:10.1002/mds.23566 · Cited by 175
Small Intestinal Bacterial Overgrowth: Diagnosis and Treatment
Gasbarrini, A., Lauritano, E. C., Gabrielli, M., Scarpellini, E., Lupascu, A., Ojetti, V., & Gasbarrini, G. (2007) · Digestive Diseases · doi:10.1159/000103892 · Cited by 159 · cited 1×
“Another intestinal abnormality in PD is small intestinal bacterial overgrowth (SIBO), where the bacterial density of small intestine is above 10(5) colony-forming units/ml and the colonic bacterial species are present in the small intestine [33].”
BackgroundPilot study of H2 therapy in Parkinson's disease: A randomized double‐blind placebo‐controlled trial
Yoritaka, A., Takanashi, M., Hirayama, M., Nakahara, T., Ohta, S., & Hattori, N. (2013) · Movement Disorders · doi:10.1002/mds.25375 · Cited by 158 · cited 2×
“We and others have previously reported that hydrogen water prevents development of PD in the 6-OH-DA-induced rat model of PD [22, 43], the MPTP-induced mouse model of PD [23], and PD patients [24].”
BackgroundSelf-citationOlfaction and Parkinson's syndromes: its role in differential diagnosis
Katzenschlager, R., & Lees, A. J. (2004) · Current Opinion in Neurology · doi:10.1097/01.wco.0000137531.76491.c2 · Cited by 157 · cited 1×
“In accordance with these observations, the smell test [4] and cardiac meta-iodobenzylguanidine scintigraphy [5] are useful methods to diagnose early PD.”
ResultHelicobacter pylori infection is associated with worse severity of Parkinson's disease
Tan, A. H., Mahadeva, S., Marras, C., Thalha, A. M., Kiew, C. K., Yeat, C. M., Ng, S. W., Ang, S. P., Chow, S. K., Loke, M. F., et al. (2014) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2014.12.009 · Cited by 148 · cited 1×
“Although not directly relevant to intestinal microbiota, it is interesting to note Helicobacter pylori infection is associated with worsening of PD [37, 38].”
BackgroundHydrogen from intestinal bacteria is protective for Concanavalin A-induced hepatitis
Kajiya, M., Sato, K., Silva, M. J. B., Ouhara, K., Phi, M., Shanmugam, K. T., & Kawai, T. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.06.024 · Cited by 136 · cited 1×
“The effect of hydrogen-producing intestinal bacteria has been demonstrated only in Concanavarin A (ConA)-induced hepatitis [44], but not in PD.”
BackgroundLipopolysaccharide Toxicity-Regulating Proteins in Bacteremia
Froon, A. H. M., Dentener, M. A., Greve, J. W. M., Ramsay, G., & Buurman, W. A. (1995) · Journal of Infectious Diseases · doi:10.1093/infdis/171.5.1250 · Cited by 125
Ito, M., Hirayama, M., Yamai, K., Goto, S., Ito, M., Ichihara, M., & Ohno, K. (2012) · Medical Gas Research · doi:10.1186/2045-9912-2-15 · Cited by 110 · cited 2×
“We previously reported that the total amount of breath hydrogen in PD patients was lower than those in healthy controls [43], which is in accordance with our current observation that hydrogen-producing bacteria was lower in PD patients.”
BackgroundResultSelf-citationIntestinal flora and human health.
MITSUOKA, T. (1996) · PubMed · Cited by 108
A Novel Acute-Phase Marker: Lipopolysaccharide Binding Protein (LBP)
Schumann, R. R., & Zweigner, J. (1999) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.1999.047 · Cited by 106
Neuropeptide Y, galanin, and leptin release in obese women and in women with anorexia nervosa
Baranowska, B., Wasilewska-Dziubińska, E., Radzikowska, M., Pęlonowski, A., & Roguski, K. (1997) · Metabolism · doi:10.1016/s0026-0495(97)90136-0 · Cited by 100
Ding, P. ‐., & Jin, L. J. (2014) · Journal of Periodontal Research · doi:10.1111/jre.12081 · Cited by 86 · cited 1×
“LBP plays a key role in the innate immune response to Gram-negative bacterial challenge [50].”
BackgroundCross-Cultural Comparison of Data Using the Odor Stick Identification Test for Japanese (OSIT-J)
Kobayashi, M., Saito, S., Kobayakawa, T., Deguchi, Y., & Costanzo, R. M. (2006) · Chemical Senses · doi:10.1093/chemse/bjj037 · Cited by 81 · cited 2×
“Abbreviations: PD, Parkinson’s disease; LPS, lipopolysaccharide; LBP, lipopolysaccharide-binding protein; DAO, diamine oxidase; UPDRS, Unified Parkinson’s Disease Rating Scale; MMSE, Mini Mental Sate Examination; MoCA-J, Japanese version of the Montreal Cognitive Assessment; FAB, Frontal Assessment Battery at bedside;…”
MethodHirayama, M., Hakusui, S., Koike, Y., Ito, K., Kato, T., Ikeda, M., Hasegawa, Y., & Takahashi, A. (1995) · Journal of the Autonomic Nervous System · doi:10.1016/0165-1838(95)00002-f · Cited by 73 · cited 1×
“In accordance with these observations, the smell test [4] and cardiac meta-iodobenzylguanidine scintigraphy [5] are useful methods to diagnose early PD.”
ResultSelf-citationSakaguchi, S., Saito, M., Tsuji, H., Asahara, T., Takata, O., Fujimura, J., Nagata, S., Nomoto, K., & Shimizu, T. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.01724-09 · Cited by 62
Self-citationPeptidoglycan recognition protein genes and risk of Parkinson's disease
Goldman, S. M., Kamel, F., Ross, G. W., Jewell, S. A., Marras, C., Hoppin, J. A., Umbach, D. M., Bhudhikanok, G. S., Meng, C., Korell, M., et al. (2014) · Movement Disorders · doi:10.1002/mds.25895 · Cited by 52 · cited 1×
“genes are associated with the risk of PD [30].”
BackgroundBarbero (2014) · doi:10.1016/j · Cited by 1
(2014) · Institutional Repository University of Antioquia (University of Antioquia) · doi:10.1371/journal.pone
Cited by
Cryan, J. F., O'Riordan, K. J., Cowan, C. S. M., Sandhu, K. V., Bastiaanssen, T. F. S., Boehme, M., Codagnone, M. G., Cussotto, S., Fulling, C., Golubeva, A. V., et al. (2019) · Physiological Reviews · doi:10.1152/physrev.00018.2018 · Cited by 5,286
Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease
Sampson, T. R., Debelius, J. W., Thron, T., Janssen, S., Shastri, G. G., Ilhan, Z. E., Challis, C., Schretter, C. E., Rocha, S., Gradinaru, V., et al. (2016) · Cell · doi:10.1016/j.cell.2016.11.018 · Cited by 3,622
“Conversely, the gut microbiomes in human subjects with PD contain an increased abundance of Proteobacteria (Hasegawa et al., 2015; Keshavarzian et al., 2015; Scheperjans et al., 2015; Unger et al., 2016), remarkably similar to our results in mice.”
InfluentialThe gut microbiota–brain axis in behaviour and brain disorders
Morais, L. H., Schreiber, H. L., & Mazmanian, S. K. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-020-00460-0 · Cited by 2,149
The central nervous system and the gut microbiome
Sharon, G., Sampson, T. R., Geschwind, D. H., & Mazmanian, S. K. (2016) · Cell · doi:10.1016/j.cell.2016.10.027 · Cited by 1,513
“Concurrently, individuals afflicted with Parkinson’s disease (PD) display significantly different fecal and mucosal microbial populations (Hasegawa et al., 2015; Keshavarzian et al., 2015; Scheperjans et al., 2015).”
BackgroundCattaneo, A., Cattane, N., Galluzzi, S., Provasi, S., Lopizzo, N., Festari, C., Ferrari, C., Guerra, U. P., Paghera, B., Muscio, C., et al. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.08.019 · Cited by 1,382
“Two interesting studies (Keshavarzian et al., 2015; Hasegawa et al., 2015) provide evidence that pro-inflammatory dysbiosis could trigger inflammation-induced misfolding of α -synuclein the development of PD.”
Background
Metadata
- Authors
- Hasegawa, S., Goto, S., Tsuji, H., Okuno, T., Asahara, T., Nomoto, K., Shibata, A., Fujisawa, Y., Minato, T., Okamoto, A., Ohno, K., & Hirayama, M.
- Affiliations
- Nagoya University (JP)
- Yakult Central Institute (JP)
- Aichi University of Education (JP)
- Corresponding author
- Ohno, Kinji
- Hirayama, Masaaki
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2015-11-05
- Volume
- 10
- Issue
- 11
- Pages
- e0142164
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4634857
- OpenAlex
- W2097335121
- Cited by
- 523
- References
- 51
- Citations by year
- 2026: 28 · 2025: 38 · 2024: 51 · 2023: 79 · 2022: 70 · 2021: 80 · 2020: 57 · 2019: 41 · 2018: 51 · 2017: 22 · 2016: 6
- FWCI
- 11.44
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Ministry of Education, Culture, Sports, Science and Technology
- Ministry of Health, Labour and Welfare
- Japan Society for the Promotion of Science (15K09350, 25870317)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- Parkinson's disease, gut dysbiosis, lipopolysaccharide-binding protein, intestinal permeability, Lactobacillus, Clostridium coccoides, Bacteroides fragilis, hydrogen-producing bacteria, Lactobacillus gasseri, constipation, diamine oxidase, intestinal mucosal integrity, fecal microbiota, disease progression
- MeSH terms
- Lipopolysaccharide-Binding Protein, Acute-Phase Proteins, Aged, Bacteria, Carrier Proteins, Constipation, DNA, Bacterial, Feces, Female, Humans, Intestinal Mucosa, Male, Membrane Glycoproteins, Parkinson Disease, Permeability, RNA, Ribosomal, 16S, Case-Control Studies, Metagenome, Dysbiosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.